Table 1. Summary of selected end points... | American Society of Hematology

Table 1.

Summary of selected end points from pivotal randomized trials of 2G-TKIs vs imatinib

Outcome*	DASISION, %		ENESTnd, %			BFORE, %
	Dasatinib	Imatinib	Nilotinib, mg†		Imatinib	Bosutinib	Imatinib
	Dasatinib	Imatinib	300	400	Imatinib	Bosutinib	Imatinib
3-mo BCR-ABL/ABL <10%	84	64	90.6	89.2	69.2	75.2	57.3
12-mo MMR	46	28	44	43	22	47.2	36.9
5-y MMR	76	64	77	77	60	—	—
5-y MR4.5	42	33	53.5	52.3	31.4	—	—
5-y sustained MR4.5	NR	NR	41	44	26	—	—
Transformation to AP/BP	4.6	7.3	<1	<1	4	1.6	2.5
OS	91	90	93.7	96.2	91.7	99.6‡	97.9‡
CML-related deaths	3.5	6.6	2.1	1.4	5.6	NR	NR
PFS	85	86	92.2	95.8	91.0	3.7§	6.4§
Remain on therapy	61	63	59.9	61.9	49.8	78	73.2

Outcome*	DASISION, %		ENESTnd, %			BFORE, %
	Dasatinib	Imatinib	Nilotinib, mg†		Imatinib	Bosutinib	Imatinib
	Dasatinib	Imatinib	300	400	Imatinib	Bosutinib	Imatinib
3-mo BCR-ABL/ABL <10%	84	64	90.6	89.2	69.2	75.2	57.3
12-mo MMR	46	28	44	43	22	47.2	36.9
5-y MMR	76	64	77	77	60	—	—
5-y MR4.5	42	33	53.5	52.3	31.4	—	—
5-y sustained MR4.5	NR	NR	41	44	26	—	—
Transformation to AP/BP	4.6	7.3	<1	<1	4	1.6	2.5
OS	91	90	93.7	96.2	91.7	99.6‡	97.9‡
CML-related deaths	3.5	6.6	2.1	1.4	5.6	NR	NR
PFS	85	86	92.2	95.8	91.0	3.7§	6.4§
Remain on therapy	61	63	59.9	61.9	49.8	78	73.2

AP, accelerated phase; BP, blast phase; MMR, major MR; NR, not reached; PFS, progression-free survival.

5-y data presented for DASISION and ENESTnd and 1-y data for BFORE unless otherwise specified.

Twice daily.

At 12 mo.

EFS-defining events at 12 mo.